Clinical study of amphotericin B nebulized inhalation in the prevention of invasive fungal infections of the lungs in artificial liver therapy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400094386

Enrollment

Unknown

Registered

2024-12-22

Start date

2025-01-01

Completion date

Unknown

Last updated

2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe liver disease

Interventions

Treatment group (AmB nebulization during artificial liver) :Amphotericin B nebulization

Control group (no AmB nebulization):None

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Patients who meet the criteria for severe liver disease [Guidelines for the Diagnosis and Management of Liver Failure (2018 edition)] and consent to artificial liver therapy.

Exclusion criteria

Exclusion criteria: 1. patients with pre-existing pulmonary fungal infections; 2. patients with antifungal therapy; 3. patients with allergy to amphotericin B; 4. patients who cannot be nebulized.

Design outcomes

Primary

Measure	Time frame
Percentage of fungal infections in the lungs, peripheral blood TBNK, cytokines, liver function, renal function indices, changes in coagulation, MELD score, intestinal flora, improvement rate and mortality rate of the selected cases after starting artificial liver therapy.;	—

Countries

China

Contacts

Public ContactLifei Yu

Affiliated hangzhou first people's hospital, zhejiang university school of medicine

yulifei@zju.edu.cn+86 15858199250

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026